Clinical Trial: NRG BR004

NRG BR004

Status: Closed

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

BR004 is closed to accrual, effective May 20, 2022.